Fennec Pharmaceuticals (FENC) CMO gains 168 shares as award vests

Rhea-AI Filing Summary

Fennec Pharmaceuticals Inc. reported that Chief Medical Officer Pierre Sargis Sayad acquired 168 Common Shares on July 31, 2026 through a release of restrictions on shares originally awarded on March 28, 2025. The award had a stated per-share price of $0.00, increasing his direct ownership to 21,351 Common Shares.

Insider Trade Summary

Net Buyer: 168 shares

Net Buy 1 txn

Insider Sayad Pierre Sargis

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Shares F1	168	$0.00	$0.00

Holdings After Transaction: Common Shares — 21,351 shares (Direct)

Footnotes (1)

1. F1. Represents shares released from restriction from shares awarded 3/28/2025.

Key Figures

Common shares acquired: 168 Common Shares Per-share transaction price: $0.0000 per share Shares owned after transaction: 21,351 Common Shares +1 more

4 metrics

Common shares acquired 168 Common Shares Grant, award, or other acquisition on July 31, 2026

Per-share transaction price $0.0000 per share Stated price for the July 31, 2026 share release

Shares owned after transaction 21,351 Common Shares Direct holdings of Pierre Sargis Sayad following the award

Original award date March 28, 2025 Date the restricted shares were initially awarded

Key Terms

Grant, award, or other acquisition, Common Shares, shares released from restriction

3 terms

Grant, award, or other acquisition regulatory

"Transaction code A described as grant, award, or other acquisition"

Common Shares financial

"Security title reported as Common Shares for this insider award"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

shares released from restriction financial

"Represents shares released from restriction from shares awarded 3/28/2025."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/03/2026 - 04:06 PM Accepted by SEC EDGAR 08/03/2026 - 04:05 PM Learn about SEC filing dates

FAQ

What insider transaction did Fennec Pharmaceuticals (FENC) report for Pierre Sargis Sayad?

Chief Medical Officer Pierre Sargis Sayad acquired 168 Common Shares of Fennec Pharmaceuticals on July 31, 2026. The shares were released from restriction on a prior award dated March 28, 2025, raising his direct holdings to 21,351 Common Shares.

How many Fennec Pharmaceuticals (FENC) shares were involved and at what price?

The transaction involved 168 Common Shares with a stated transaction price of $0.00 per share. This reflects a release of restricted shares rather than an open-market purchase or sale, and therefore did not involve cash consideration at the time of vesting.

What is Pierre Sargis Sayad’s Fennec Pharmaceuticals (FENC) shareholding after this transaction?

Following the July 31, 2026 award vesting, Pierre Sargis Sayad directly owns 21,351 Common Shares of Fennec Pharmaceuticals. This total includes the 168 shares released from restriction that were originally granted on March 28, 2025.

What is the nature of the 168-share award reported by Fennec Pharmaceuticals (FENC)?

The 168 Common Shares represent shares released from restriction on stock originally awarded on March 28, 2025. This indicates a vesting of previously granted equity compensation, not a new market purchase or sale of Fennec Pharmaceuticals shares.

Was the Fennec Pharmaceuticals (FENC) insider transaction under a Rule 10b5-1 trading plan?

No. The transaction for 168 Common Shares is not designated as occurring under a Rule 10b5-1 trading plan. It reflects the scheduled release of restrictions on a prior equity award to the company’s Chief Medical Officer.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sayad Pierre Sargis

(Last) (First) (Middle)

C/O FENNEC PHARMACEUTICALS, INC.

PO BOX 13628, 68 TW ALEXANDER DRIVE

(Street)

RESEARCH TRIANGLE PARK NORTH CAROLINA 27709

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares(1)	07/31/2026		A		168	A	$0	21,351	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares released from restriction from shares awarded 3/28/2025.

	/s/ Pierre Sayad	08/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)